Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant cyclophosphamide as GvHD prophylaxis, using a database with information from historical clinic data.
The overall aim of the study is to to analize CMVi after PTCy for GVHD prophylaxis, with a detailed description of CMVi and recurrences, direct and indirect consequences, in a HSCT population comparing two cohorts: haploidentical HSCT vs no haploidentical HSCT
Study Type
OBSERVATIONAL
Enrollment
300
Maria Jesus Pascual
Málaga, Spain
Incidence of CMVi in HSCT with PT-Cy and CMVi requiring pre-emptive therapy (significant CMVi)
Time frame: 1 year
Median time to CMVi
Time frame: 1 year
Cumulative incidence of PET-CMVi by day +100, +180 and +365.
Time frame: 1 year
Overall survival by day +100, +180 and +365
Time frame: 1 year
Overall mortality by day +100, +180 and +365
Time frame: 1 year
Non-relapse mortality by day +100, +180 and +365
Time frame: 1 year
CMV indirect effects incidence
Hospital admissions, secondary infections, secondary toxicity.
Time frame: 1 year
Incidence of CMVi recurrent episodes
Time frame: 1 year
CMV disease
Time frame: 1 year
CMV direct mortality
Time frame: 1 year
Cumulative incidence of II-IV aGvHD
Time frame: 1 year
Cumulative incidence of moderate-severe cGvHD
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.